Navigation Links
Pest control research leads to pain control discovery

A newly discovered enzyme inhibitor, identified by researchers originally looking for biological pest controls, may lead to pain relief for sufferers of arthritis and other inflammatory diseases, say researchers at the University of California, Davis. The finding, hailed by a noted inflammatory disease expert "as the most important discovery in inflammation in more than a decade," may also reduce side effects associated with the painkiller, Vioxx.

Lead author Kara Schmelzer, a post-doctoral researcher in principal investigator Bruce Hammock's lab, tested the novel compounds on rodents and found them to be as potent at a low-dose as Vioxx and Celebrex, but without the changes in blood chemistry linked to heart attacks. Vioxx and Celebrex belong to a class of drugs known as Cox-2 inhibitors. The enzyme targeted by the newly discovered inhibitors is also found in humans. (Enzymes are proteins that speed up chemical reactions.)

"The reason this is so exciting is that this is a novel way to reduce inflammation, with a combination therapy," Schmelzer said. "We're going after a new enzyme target, not going after the Cox-2 inhibitors."

Their research is reported in a paper entitled "Enhancement of Antinociception by Coadministration of Nonsteroidal Anti-Inflammatory Drugs and Soluble Epoxide Hydrolase Inhibitors," published in the current edition of Proceedings of the National Academy of Sciences.

"Our laboratory was initially interested in regulating the development of insect larvae," said Hammock, a distinguished professor of entomology and member of the National Academy of Sciences. The discovery switched the focus of the research from "pest control to pain control."

M. Eric Gershwin, chief of the Division of Rheumatology, Allergy and Clinical Immunology at the UC Davis School of Medicine and a distinguished professor of medicine, called the discovery "the most important discovery in inflammation in more than a decade." Gershwi n, who was not affiliated with this study, is noted for his research on rheumatoid arthritis and other inflammatory diseases. His lab investigates the mechanisms leading to immunological alterations and autoimmunity.

As of 2004, physicians prescribed anti-inflammatory medication for more than 73 million patients. But many of the people suffer from pharmacological properties or side effects of the medications. Merck, the pharmaceutical company that manufactured and marketed Vioxx, a Cox-2 selective nonsteroidal anti-inflammatory drug (NSAID), voluntarily pulled the pain killer from the market in September 2004 due to safety concerns. A 12-month study, published in 2000, showed a four-fold increased risk of heart attacks. Merck hopes to replace it with another medication, Acoxia.

However, the class of drugs benefits millions of sufferers from inflammation and pain, Hammock said. The UC Davis study may mean a solution to the dilemma of whether to use the drugs.

"Combination therapies have long been used to treat inflammation while reducing side effects," Schmelzer wrote. She said the present study was designed to evaluate the therapeutic potential of combination treatment with NSAIDs and enzyme inhibitors (a previously undescribed soluble epoxide hydrolase inhibitor or sEHIs) in lipopolysaccharide (LPS)-challenged mice.

"We used LPS as an inflammatory agent, which is a component of some bacterial cell walls," said, co-author Steven Jinks. His laboratory examined the effects of these compounds in rodent inflammatory pain ehavior models. "Inflammatory mediators sensitize pain receptors and cause the animal to withdraw more quickly from a noxious stimulus, an indication of 'hyperalgesia' or heightened response to a painful stimulus. The sEH inhibitors reverse hyperalgesia and bring their withdrawal reaction back into the normal range.

Hammock said "these sEHIs are of similar or greater potency in reducing inflammation in rodent s to Vioxx, but also when combined with Vioxx can dramatically reduce the concentrations of the Cox 2 inhibitor needed," Hammock said.

"The combination of Vioxx with the new sEHIs shifts blood chemistry toward the normal condition which may reduce the tendency toward blood clots," said UC Davis scientist Bora Inceoglu, a post-doctoral researcher and member of the research team.


'"/>

Source:University of California - Davis


Related biology news :

1. Ancient olfaction protein is shared by many bugs, offering new pest control target
2. Gene variations explain drug dose required to control seizures
3. U-M scientists find genes that control growth of common skin cancer
4. Scientists discuss improved biopesticides for locust control in West Africa
5. Insight into natural cholesterol control suggests novel cholesterol-lowering therapy
6. To control germs, scientists deploy tiny agents provocateurs
7. Cooperation is key—a new way of looking at MicroRNA and how it controls gene expression
8. Master gene controls healing of skin in fruit flies and mammals
9. Remote control flies? Fly behavior controlled by laser light
10. Internet viruses help ecologists control invasive species
11. DNA constraints control structure of attached macromolecules
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/24/2017)... -- The Controller General of Immigration from Maldives Mr. ... have received the prestigious international IAIR Award for the most innovative high ... ... Maldives Immigration Controller ... (small picture on the right) have received the IAIR award for the ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer ... that they have entered into a multiyear collaboration to identify and characterize novel ... additional tools for gene editing across all applications. , Under the terms of ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Wound Market with the addition of its newest module, US Hemostats & Sealants. ... for thrombin hemostats, absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used ...
(Date:10/12/2017)... Diego, CA (PRWEB) , ... ... ... (https://www.onramp.bio/ ) has launched Rosalind™, the first-ever genomics analysis platform specifically ... all bioinformatics complexity. Named in honor of pioneering researcher Rosalind Franklin, who ...
(Date:10/11/2017)... YORBA LINDA, CA (PRWEB) , ... October 11, ... ... adapted to upregulate any gene in its endogenous context, enabling overexpression experiments and ... activation (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function ...
Breaking Biology Technology: